There’s a frustrating fact about today’s immunotherapies for cancer. While sometimes they work beautifully—completely eliminating or greatly reducing cancer in particular patients—other times they don’t work at all. It’s a mystery.
Colorectal cancer is the second leading cause of cancer deaths worldwide and the third most diagnosed cancer, affecting over a million people annually. The problem worsens if the tumor is metastatic, meaning it moves from the original organ to other pa…
Researchers from King’s College have led research that has resulted in the publication of first-of-their-kind guidelines that seek to standardize how clinicians measure the immune response of patients who have myelodysplastic syndromes (MDS), a type of…
The primary goal in cancer drug research is not merely to discover compounds that can destroy cancer cells, but to develop methods that specifically target and deliver these agents to cancer cells, sparing healthy ones.
A number of cancers, including certain brain and liver tumors, as well as myeloid leukemias, are driven by mutations in the enzyme isocitrate dehydrogenase 1, or IDH1. Drugs that block mutated IDH1 (mIDH1) have recently come onto the market and effecti…
Immunotherapy can be a highly effective treatment for non-small cell lung cancer (NSCLC), but some patients are resistant to the therapy or develop intolerable side effects.
Early findings from a small clinical trial provide evidence that a new cellular immunotherapy approach may be effective in treating metastatic solid tumors. In the trial, researchers from the National Institutes of Health (NIH) genetically engineered n…
A clinical trial has shown that a new drug combination utilized before surgery completely eliminated or shrunk melanoma tumors in 70% of trial participants. The phase II clinical trial, NeoACTIVATE, enrolled patients with stage 3 melanoma; trial result…
Using genetic engineering techniques, investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy have designed a novel type of cell to recognize and f…
A study led by the Hospital del Mar Research Institute, with Cima University of Navarra and Pompeu Fabra University, has identified a group of small molecules exclusive to liver tumors that could be key to developing cancer vaccines. These are micropro…
